National Institutes of Health
DAVID Bioinformatics

Functional Annotation Chart

Help and Manual

Current Gene List: condition_specific_gene_list
Current Background: Homo sapiens
2052 DAVID IDs

Options

Rerun Using Options | Create Sublist

157 chart records

Download File

Sublist	Category	Term	RT	Genes	Count	%	P-Value	Benjamini
	WIKIPATHWAYS	Cytoplasmic ribosomal proteins	RT		74	3.6	2.7E-49	2.0E-46
	WIKIPATHWAYS	VEGFA VEGFR2 signaling	RT		118	5.8	1.8E-14	6.4E-12
	WIKIPATHWAYS	Modulators of TCR signaling and T cell activation	RT		33	1.6	5.0E-13	1.2E-10
	WIKIPATHWAYS	mRNA processing	RT		48	2.3	1.5E-11	2.8E-9
	WIKIPATHWAYS	TNF alpha signaling pathway	RT		37	1.8	2.7E-10	3.9E-8
	WIKIPATHWAYS	T cell receptor signaling pathway	RT		33	1.6	5.2E-10	6.3E-8
	WIKIPATHWAYS	Th17 cell differentiation pathway	RT		30	1.5	7.7E-9	8.0E-7
	WIKIPATHWAYS	Measles virus infection	RT		45	2.2	1.2E-8	1.1E-6
	WIKIPATHWAYS	T cell activation SARS CoV 2	RT		33	1.6	5.6E-8	4.5E-6
	WIKIPATHWAYS	Ebola virus infection in host	RT		42	2.0	6.7E-8	4.9E-6
	WIKIPATHWAYS	Hepatitis B infection	RT		45	2.2	3.7E-7	2.4E-5
	WIKIPATHWAYS	Translation factors	RT		22	1.1	6.9E-7	4.2E-5
	WIKIPATHWAYS	Cancer immunotherapy by PD 1 blockade	RT		14	0.7	1.5E-6	8.5E-5
	WIKIPATHWAYS	Apoptosis	RT		30	1.5	2.5E-6	1.3E-4
	WIKIPATHWAYS	T cell antigen receptor TCR pathway during Staphylococcus aureus infection	RT		24	1.2	2.8E-6	1.3E-4
	WIKIPATHWAYS	16p11 2 proximal deletion syndrome	RT		26	1.3	1.2E-5	5.6E-4
	WIKIPATHWAYS	TNF related weak inducer of apoptosis TWEAK signaling pathway	RT		17	0.8	1.4E-5	6.0E-4
	WIKIPATHWAYS	Initiation of transcription and translation elongation at the HIV 1 LTR	RT		15	0.7	2.9E-5	1.2E-3
	WIKIPATHWAYS	Proteasome degradation	RT		22	1.1	3.7E-5	1.4E-3
	WIKIPATHWAYS	Immune response to tuberculosis	RT		12	0.6	4.6E-5	1.7E-3
	WIKIPATHWAYS	EGF EGFR signaling pathway	RT		41	2.0	5.9E-5	2.0E-3
	WIKIPATHWAYS	Electron transport chain OXPHOS system in mitochondria	RT		30	1.5	1.0E-4	3.3E-3
	WIKIPATHWAYS	Calcium mediated T cell apoptosis involved in inclusion body myositis	RT		11	0.5	1.0E-4	3.3E-3
	WIKIPATHWAYS	Thyroid stimulating hormone TSH signaling pathway	RT		20	1.0	1.4E-4	4.3E-3
	WIKIPATHWAYS	Interferon type I signaling pathways	RT		19	0.9	1.7E-4	4.8E-3
	WIKIPATHWAYS	Prolactin signaling pathway	RT		23	1.1	2.2E-4	6.2E-3
	WIKIPATHWAYS	Metabolic reprogramming in colon cancer	RT		16	0.8	2.4E-4	6.6E-3
	WIKIPATHWAYS	TGF beta signaling pathway	RT		34	1.7	2.9E-4	7.4E-3
	WIKIPATHWAYS	AGE RAGE pathway	RT		21	1.0	3.2E-4	8.0E-3
	WIKIPATHWAYS	HDAC6 interactions in the central nervous system	RT		30	1.5	3.5E-4	8.4E-3
	WIKIPATHWAYS	PDGF pathway	RT		15	0.7	5.0E-4	1.1E-2
	WIKIPATHWAYS	Chromosomal and microsatellite instability in colorectal cancer	RT		22	1.1	5.0E-4	1.1E-2
	WIKIPATHWAYS	nsp1 from SARS CoV 2 inhibits translation initiation in the host cell	RT		9	0.4	5.3E-4	1.2E-2
	WIKIPATHWAYS	Nonalcoholic fatty liver disease	RT		37	1.8	6.2E-4	1.3E-2
	WIKIPATHWAYS	Nanomaterial induced apoptosis	RT		10	0.5	6.3E-4	1.3E-2
	WIKIPATHWAYS	IL 4 signaling pathway	RT		17	0.8	6.4E-4	1.3E-2
	WIKIPATHWAYS	T cell receptor and co stimulatory signaling	RT		12	0.6	6.5E-4	1.3E-2
	WIKIPATHWAYS	Network map of SARS CoV 2 signaling pathway	RT		48	2.3	7.1E-4	1.4E-2
	WIKIPATHWAYS	IL 2 signaling pathway	RT		14	0.7	7.5E-4	1.4E-2
	WIKIPATHWAYS	Oncostatin M signaling pathway	RT		18	0.9	8.6E-4	1.5E-2
	WIKIPATHWAYS	IL 18 signaling pathway	RT		18	0.9	8.6E-4	1.5E-2
	WIKIPATHWAYS	IL 9 signaling pathway	RT		9	0.4	8.8E-4	1.5E-2
	WIKIPATHWAYS	Ciliary landscape	RT		47	2.3	9.6E-4	1.6E-2
	WIKIPATHWAYS	Pathogenesis of SARS CoV 2 mediated by nsp9 nsp10 complex	RT		10	0.5	9.7E-4	1.6E-2
	WIKIPATHWAYS	Apoptosis modulation and signaling	RT		25	1.2	9.8E-4	1.6E-2
	WIKIPATHWAYS	Non small cell lung cancer	RT		21	1.0	1.1E-3	1.7E-2
	WIKIPATHWAYS	TAR syndrome	RT		19	0.9	1.3E-3	2.1E-2
	WIKIPATHWAYS	TCA cycle aka Krebs or citric acid cycle	RT		9	0.4	1.4E-3	2.1E-2
	WIKIPATHWAYS	Acute viral myocarditis	RT		23	1.1	1.8E-3	2.6E-2
	WIKIPATHWAYS	Photodynamic therapy induced unfolded protein response	RT		11	0.5	1.9E-3	2.8E-2
	WIKIPATHWAYS	Parkin ubiquitin proteasomal system pathway	RT		20	1.0	2.3E-3	3.3E-2
	WIKIPATHWAYS	Endoplasmic reticulum stress response in coronavirus infection	RT		15	0.7	2.3E-3	3.3E-2
	WIKIPATHWAYS	Unfolded protein response	RT		10	0.5	2.9E-3	4.0E-2
	WIKIPATHWAYS	Host pathogen interaction of human coronaviruses interferon induction	RT		12	0.6	3.1E-3	4.1E-2
	WIKIPATHWAYS	IL6 signaling pathway	RT		14	0.7	3.5E-3	4.4E-2
	WIKIPATHWAYS	Inflammatory bowel disease signaling	RT		14	0.7	3.5E-3	4.4E-2
	WIKIPATHWAYS	Fas ligand pathway and stress induction of heat shock proteins	RT		14	0.7	3.5E-3	4.4E-2
	WIKIPATHWAYS	PDGFR beta pathway	RT		11	0.5	3.6E-3	4.4E-2
	WIKIPATHWAYS	Allograft rejection	RT		23	1.1	3.8E-3	4.6E-2
	WIKIPATHWAYS	Interleukin 1 IL 1 structural pathway	RT		15	0.7	4.5E-3	5.3E-2
	WIKIPATHWAYS	17p13 3 YWHAE copy number variation	RT		9	0.4	4.5E-3	5.3E-2
	WIKIPATHWAYS	Pathways affected in adenoid cystic carcinoma	RT		18	0.9	5.0E-3	5.7E-2
	WIKIPATHWAYS	Ferroptosis	RT		18	0.9	5.0E-3	5.7E-2
	WIKIPATHWAYS	RANKL RANK signaling pathway	RT		15	0.7	5.4E-3	6.1E-2
	WIKIPATHWAYS	Common pathways underlying drug addiction	RT		13	0.6	6.7E-3	7.4E-2
	WIKIPATHWAYS	Pancreatic adenocarcinoma pathway	RT		22	1.1	7.1E-3	7.8E-2
	WIKIPATHWAYS	miRNA regulation of DNA damage response	RT		19	0.9	7.6E-3	8.2E-2
	WIKIPATHWAYS	Serotonin HTR1 group and FOS pathway	RT		12	0.6	8.1E-3	8.6E-2
	WIKIPATHWAYS	Head and neck squamous cell carcinoma	RT		19	0.9	8.8E-3	9.2E-2
	WIKIPATHWAYS	TLR4 signaling and tolerance	RT		10	0.5	9.4E-3	9.5E-2
	WIKIPATHWAYS	IL 19 signaling pathway	RT		10	0.5	9.4E-3	9.5E-2
	WIKIPATHWAYS	DNA damage response	RT		18	0.9	9.4E-3	9.5E-2
	WIKIPATHWAYS	Exercise induced circadian regulation	RT		14	0.7	9.8E-3	9.7E-2
	WIKIPATHWAYS	16p11 2 distal deletion syndrome	RT		11	0.5	9.9E-3	9.7E-2
	WIKIPATHWAYS	FOXP3 in COVID 19	RT		7	0.3	1.0E-2	1.0E-1
	WIKIPATHWAYS	Corticotropin releasing hormone signaling pathway	RT		22	1.1	1.2E-2	1.1E-1
	WIKIPATHWAYS	Novel intracellular components of RIG I like receptor pathway	RT		16	0.8	1.2E-2	1.2E-1
	WIKIPATHWAYS	Leptin signaling pathway	RT		18	0.9	1.3E-2	1.2E-1

Sublist	Category	Term	RT	Genes	Count	%	P-Value	Benjamini
☐	WIKIPATHWAYS	5q35 copy number variation	RT		25	1.2	1.3E-2	1.2E-1
☐	WIKIPATHWAYS	IL 7 signaling pathway	RT		8	0.4	1.3E-2	1.2E-1
☐	WIKIPATHWAYS	TGF beta receptor signaling	RT		15	0.7	1.3E-2	1.2E-1
☐	WIKIPATHWAYS	SARS CoV 2 innate immunity evasion and cell specific immune response	RT		17	0.8	1.4E-2	1.2E-1
☐	WIKIPATHWAYS	IL 3 signaling pathway	RT		14	0.7	1.4E-2	1.2E-1
☐	WIKIPATHWAYS	Quercetin and Nf kB AP 1 induced apoptosis	RT		7	0.3	1.5E-2	1.3E-1
☐	WIKIPATHWAYS	Interactome of polycomb repressive complex 2 PRC2	RT		7	0.3	1.5E-2	1.3E-1
☐	WIKIPATHWAYS	Thymic stromal lymphopoietin TSLP signaling pathway	RT		12	0.6	1.5E-2	1.3E-1
☐	WIKIPATHWAYS	Leukocyte intrinsic Hippo pathway functions	RT		11	0.5	1.5E-2	1.3E-1
☐	WIKIPATHWAYS	Adipogenesis	RT		28	1.4	1.6E-2	1.3E-1
☐	WIKIPATHWAYS	Envelope proteins and their potential roles in EDMD physiopathology	RT		13	0.6	1.7E-2	1.4E-1
☐	WIKIPATHWAYS	Melanoma	RT		17	0.8	1.8E-2	1.4E-1
☐	WIKIPATHWAYS	Alzheimer 39 s disease	RT		49	2.4	1.8E-2	1.5E-1
☐	WIKIPATHWAYS	Toll like receptor signaling related to MyD88	RT		10	0.5	1.9E-2	1.5E-1
☐	WIKIPATHWAYS	Toll like receptor signaling pathway	RT		23	1.1	1.9E-2	1.5E-1
☐	WIKIPATHWAYS	Circadian rhythm genes	RT		39	1.9	2.0E-2	1.5E-1
☐	WIKIPATHWAYS	Neuroinflammation and glutamatergic signaling	RT		29	1.4	2.1E-2	1.6E-1
☐	WIKIPATHWAYS	IL 5 signaling pathway	RT		11	0.5	2.2E-2	1.7E-1
☐	WIKIPATHWAYS	Androgen receptor signaling pathway	RT		20	1.0	2.3E-2	1.7E-1
☐	WIKIPATHWAYS	Purine metabolism	RT		6	0.3	2.3E-2	1.7E-1
☐	WIKIPATHWAYS	MET in type 1 papillary renal cell carcinoma	RT		15	0.7	2.4E-2	1.7E-1
☐	WIKIPATHWAYS	TGF beta receptor signaling in skeletal dysplasias	RT		15	0.7	2.4E-2	1.7E-1
☐	WIKIPATHWAYS	Alzheimer 39 s disease and miRNA effects	RT		49	2.4	2.5E-2	1.8E-1
☐	WIKIPATHWAYS	IL 1 signaling pathway	RT		14	0.7	2.6E-2	1.8E-1
☐	WIKIPATHWAYS	Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells	RT		7	0.3	2.7E-2	1.9E-1
☐	WIKIPATHWAYS	Brain derived neurotrophic factor BDNF signaling pathway	RT		28	1.4	2.8E-2	1.9E-1
☐	WIKIPATHWAYS	CAMKK2 pathway	RT		10	0.5	2.8E-2	1.9E-1
☐	WIKIPATHWAYS	Purine metabolism and related disorders	RT		8	0.4	2.9E-2	1.9E-1
☐	WIKIPATHWAYS	Vasopressin regulated water reabsorption	RT		12	0.6	3.0E-2	2.0E-1
☐	WIKIPATHWAYS	Cell cycle	RT		25	1.2	3.1E-2	2.1E-1
☐	WIKIPATHWAYS	JAK STAT signaling in the regulation of beta cells	RT		10	0.5	3.4E-2	2.2E-1
☐	WIKIPATHWAYS	Apoptosis modulation by HSP70	RT		7	0.3	3.5E-2	2.3E-1
☐	WIKIPATHWAYS	Physiological and pathological hypertrophy of the heart	RT		8	0.4	3.6E-2	2.3E-1
☐	WIKIPATHWAYS	MAPK signaling pathway	RT		45	2.2	3.6E-2	2.3E-1
☐	WIKIPATHWAYS	RAC1 PAK1 p38 MMP2 pathway	RT		16	0.8	3.7E-2	2.4E-1
☐	WIKIPATHWAYS	Photodynamic therapy induced AP 1 survival signaling	RT		13	0.6	3.7E-2	2.4E-1
☐	WIKIPATHWAYS	Pathways in cancer	RT		84	4.1	4.0E-2	2.5E-1
☐	WIKIPATHWAYS	Pro survival signaling of neuroprotectin D1	RT		6	0.3	4.3E-2	2.7E-1
☐	WIKIPATHWAYS	Glucocorticoid receptor pathway	RT		16	0.8	4.6E-2	2.9E-1
☐	WIKIPATHWAYS	Apoptosis related network due to altered Notch3 in ovarian cancer	RT		13	0.6	4.9E-2	3.0E-1
☐	WIKIPATHWAYS	miRNA regulation of prostate cancer signaling pathways	RT		9	0.4	5.1E-2	3.0E-1
☐	WIKIPATHWAYS	Gastric cancer network 2	RT		9	0.4	5.1E-2	3.0E-1
☐	WIKIPATHWAYS	NAD metabolism sirtuins and aging	RT		5	0.2	5.1E-2	3.0E-1
☐	WIKIPATHWAYS	Arsenic metabolism and reactive oxygen species generation	RT		5	0.2	5.1E-2	3.0E-1
☐	WIKIPATHWAYS	Cell interactions of the pancreatic cancer microenvironment	RT		8	0.4	5.3E-2	3.1E-1
☐	WIKIPATHWAYS	EPO receptor signaling	RT		8	0.4	5.3E-2	3.1E-1
☐	WIKIPATHWAYS	Type II interferon signaling	RT		10	0.5	5.5E-2	3.2E-1
☐	WIKIPATHWAYS	STING pathway in Kawasaki like disease and COVID 19	RT		7	0.3	5.5E-2	3.2E-1
☐	WIKIPATHWAYS	Small cell lung cancer	RT		20	1.0	5.6E-2	3.2E-1
☐	WIKIPATHWAYS	Oxidative phosphorylation	RT		14	0.7	5.6E-2	3.2E-1
☐	WIKIPATHWAYS	Pentose phosphate metabolism	RT		4	0.2	5.7E-2	3.2E-1
☐	WIKIPATHWAYS	mRNA protein and metabolite induction pathway by cyclosporin A	RT		4	0.2	5.7E-2	3.2E-1
☐	WIKIPATHWAYS	Gastrin signaling pathway	RT		23	1.1	5.8E-2	3.2E-1
☐	WIKIPATHWAYS	Intracellular trafficking proteins involved in CMT neuropathy	RT		8	0.4	6.4E-2	3.5E-1
☐	WIKIPATHWAYS	Interleukin 11 signaling pathway	RT		11	0.5	6.7E-2	3.6E-1
☐	WIKIPATHWAYS	Progeria associated lipodystrophy	RT		7	0.3	6.8E-2	3.6E-1
☐	WIKIPATHWAYS	B cell receptor signaling pathway	RT		19	0.9	6.8E-2	3.6E-1
☐	WIKIPATHWAYS	Osteoarthritic chondrocyte hypertrophy	RT		12	0.6	6.9E-2	3.6E-1
☐	WIKIPATHWAYS	MAPK cascade	RT		9	0.4	7.0E-2	3.6E-1
☐	WIKIPATHWAYS	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma	RT		6	0.3	7.0E-2	3.6E-1
☐	WIKIPATHWAYS	Mitochondrial complex I assembly model OXPHOS system	RT		13	0.6	7.0E-2	3.6E-1
☐	WIKIPATHWAYS	Aryl hydrocarbon receptor pathway	RT		11	0.5	7.6E-2	3.9E-1
☐	WIKIPATHWAYS	Acute myeloid leukemia	RT		15	0.7	7.8E-2	4.0E-1
☐	WIKIPATHWAYS	Overlap between signal transduction pathways contributing to LMNA laminopathies	RT		13	0.6	7.8E-2	4.0E-1
☐	WIKIPATHWAYS	Mitochondrial complex IV assembly	RT		9	0.4	8.1E-2	4.0E-1
☐	WIKIPATHWAYS	Type 2 papillary renal cell carcinoma	RT		9	0.4	8.1E-2	4.0E-1
☐	WIKIPATHWAYS	Estrogen signaling pathway	RT		7	0.3	8.1E-2	4.0E-1
☐	WIKIPATHWAYS	LDL influence on CD14 and TLR4	RT		7	0.3	8.1E-2	4.0E-1
☐	WIKIPATHWAYS	Ebstein Barr virus LMP1 signaling	RT		7	0.3	8.1E-2	4.0E-1
☐	WIKIPATHWAYS	Canonical NF kB pathway	RT		4	0.2	8.3E-2	4.0E-1
☐	WIKIPATHWAYS	Extrafollicular and follicular B cell activation by SARS CoV 2	RT		16	0.8	8.5E-2	4.1E-1
☐	WIKIPATHWAYS	Translation inhibitors in chronically activated PDGFRA cells	RT		11	0.5	8.6E-2	4.1E-1
☐	WIKIPATHWAYS	Genes associated with the development of rheumatoid arthritis	RT		6	0.3	8.6E-2	4.1E-1
☐	WIKIPATHWAYS	Perturbations to host cell autophagy induced by SARS CoV 2 proteins	RT		6	0.3	8.6E-2	4.1E-1
☐	WIKIPATHWAYS	Ulcerative colitis signaling	RT		6	0.3	8.6E-2	4.1E-1
☐	WIKIPATHWAYS	1p36 copy number variation syndrome	RT		19	0.9	8.7E-2	4.1E-1
☐	WIKIPATHWAYS	Neuroinflammation	RT		5	0.2	8.8E-2	4.1E-1
☐	WIKIPATHWAYS	Sudden infant death syndrome SIDS susceptibility pathways	RT		29	1.4	9.3E-2	4.3E-1
☐	WIKIPATHWAYS	Interactions between immune cells and microRNAs in tumor microenvironment	RT		11	0.5	9.6E-2	4.4E-1

1231 gene(s) from your list are not in the output.

Please cite DAVID within any publication that makes use of any methods inspired by **DAVID**.